NemaMetrix Inc. specializes in developing and manufacturing devices, consumables, and software for worm screening and phenotyping. By offering a more affordable and rapid system that supplements the traditional mouse model, the focus is on enabling scientists and researchers better to understand human diseases and explore potential treatments for high-impact disorders such as Alzheimers disease, and ALS (Lou Gehrigs Disease), and cardiac arrhythmias. The firm's ScreenChip System, a first-in-class automatic screening and phenotyping platform utilizing C. elegans as the model organism, which acquires and displays neuromuscular data in real time. The technology allows researchers rapidly to generate and collect precise whole-animal data via quick and reliable assessment of neuronal and physiological responses to genetic mutations, drug effects and other environmental changes. The ScreenChip technology is being used as a platform for investigations into aging, neurodegenerative diseases, arrhythmia cardiac diseases, developmental biology and environmental toxicology.
